SCHEMBL31342020

SCHEMBL31342020

Fc1cc(C2CCC3(CC2)OCCO3)ccc1Cl

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.36
IKBKE Q14164 1/20 0.36
TBK1 Q9UHD2 1/20 0.36
ATM Q13315 1/20 0.36
SLC6A3 Q01959 7/20 0.35
SLC6A4 P31645 6/20 0.35
RAB9A P51151 1/20 0.35
SLC6A2 P23975 5/20 0.35
CYP2D6 P10635 1/20 0.35
KCNH2 Q12809 1/20 0.35
TRPV3 Q8NET8 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RIPK1 Q13546 1/20 0.34
PDE2A O00408 1/20 0.33
TRPA1 O75762 1/20 0.33
POLB P06746 1/20 0.33
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506454 0.88 SLC6A2 (0.47) NPC1IKBKETBK1ATMSLC6A3
SCHEMBL8972310 0.86 TRPV3 (0.39) NPC1IKBKETBK1RAB9ATRPV3
SCHEMBL23484639 0.86 SLC6A4 (0.44) IKBKETBK1ATMSLC6A3SLC6A4
SCHEMBL8209225 0.82 IKBKE (0.36) NPC1IKBKETBK1RAB9ATRPV3
SCHEMBL7147196 0.82 IKBKE (0.39) NPC1IKBKETBK1RAB9ATRPV3
SCHEMBL15517006 0.80 SLC6A3 (0.42) SLC6A3SLC6A4SLC6A2CYP2D6KCNH2
SCHEMBL3542983 0.79 IKBKE (0.41) NPC1IKBKETBK1ATMSLC6A3
SCHEMBL30832447 0.79 HTR2A (0.39) NPC1IKBKETBK1SLC6A3SLC6A4
SCHEMBL1809044 0.78 TRPV3 (0.35) NPC1IKBKETBK1SLC6A3SLC6A4
SCHEMBL14403053 0.78 ESR2 (0.42) IKBKETBK1SLC6A3SLC6A4TRPV3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 US disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 NPC1 1390/4885IKBKE 259/4885TBK1 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.